WaveStrum Life Sciences (@WaveStrumLS) header
WaveStrum Life Sciences (@WaveStrumLS) profile picture

Med student's healthcare thoughts and biotech portfolio. Christian. šŸ‡ŗšŸ‡ø.

USA
Joined July 2025
Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)Photo by WaveStrum Life Sciences (@WaveStrumLS)
Sharing some of my diligence regarding $PEPG, which helps explain why I remain quite bullish into the 10mg / kg MAD readout. I may share more if I have time to get the rest into a distributable format and think it adds something. The headline takeaway is twofold. One, I think the outlier in the 5mg / kg MAD has little bearing on its chances of EDODM1 continuing to show best in disease efficacy in the higher MAD cohorts like it showed it in the SAD cohorts. Two, I think the EDO51 safety data and how it has tracked with EDODM1 substantially increases the likelihood there will be no SAEs at the 10mg / kg MAD dose for EDODM1, and EDODM1 will deliver a strong and commercially competitive safety profile. $PEPG is a one drug company, early stage, and the most advanced drug in its class. So, efficacy and safety risks will always exist and can never be fully ruled out. If EDODM1 fails, it's over and the stock will be crushed, albeit perhaps some value can still be extracted from the remaining cash balance given the heavy institutional ownership and sway over management. This remains a very risky investment. However, if it's successful, I would say that it is at least a 10x return from current levels, possibly a good bit more, especially with a buyout premium, and I think the probability of a strong 10mg / kg MAD make the company highly compelling at currently trading levels if position is appropriately sized. Thread below:
5
3
3
50
23,922
What's most damning re Scorpion's true beliefs and motivations in their $ABVX short report can be seen in this tweet. Scorpion stated in their initial report (in a small font legal disclaimer) that "upon the publication of this report we intend to begin covering a substantial part of our short position". Yet, in this tweet they also claim they "we don’t think the $ABVX drug will ever make it that far". "That far" meaning the anticipated upcoming FDA approval. $ABVX closed down -9.24% end of day Friday, and is back up +4.46% in after hours trading. It is still worth about ~$7Bn and is a one drug company. If you really believed $ABVX is not going to make it through FDA approval, and of course would therefore be a true zero, and if you really stood by the merits of your short report in which you claimed this was a "biotech fraud for the ages", why on earth would you substantially close your position when $ABVX is still trading at $7Bn?! It is not even below where it was when it released its exceptional Phase III induction data!!! This contradiction, more than anything else, reveals what this report was actually about. A predatory scam to score an easy, low-risk, low IQ, get in and get out win, preying on an easily predictable short-term (largely retail) reaction, amplified by the current dynamics within the biotech market (outlined previously) and across the broader market. What's further interesting is Scorpion's track record page only lists their short performance through 2024....and over the 2022-2024 timeframe, two of the three shorts they took over that multi-year timeframe look like they may have been either neutral or a big money loser for them, depending on when they closed their position. Hardly market beating performance... scorpioncapital.com/track-re… It begs the question whether in a market where there have been plenty of opportunities to find and participate in quality shorts and a whole lot of returns to find elsewhere, these guys simply do not have the capability to find any more good short ideas, no longer even think of themselves as sharp enough to make an authentic high-conviction short, are panicking under LP pressure regarding a lack of performance, and therefore have chosen to resort to scammy and intellectually bereft tactics to try and make an easy, low-risk buck and hold on to their management fees. Scorpion probably is substantially or entirely out as they said they would be. However, imagine if the bizarre follow-up attacks on ADAR1 and Adam reflected a world in which $ABVX hadn't dropped enough to save them their performance, and they hung on to the position out of desperation for more of a drop....boy, would it be just desserts for these guys to get squeezed.
We don’t usually engage with enthusiasts ranting about their pet ticker, but in this case it helps to elaborate on our $ABVX thesis. ā€œAt least your SLNO report was based on actual in-human dataā€ - yes, but it started w the drug’s chemistry, pharmacology, and actual (vs. claimed) mechanism. We worked backward from there; same process we used for ABVX’s obefazimod . That made it trivial to predict fluid retention and congestive heart failure, and the subsequent VYKAT XR safety debacle, even though there was no such obvious human signal in the trials. We see time and time again that companies can game, fake, and/or manipulate clinical data. The incentives to do so are overwhelming; if you don’t, your stock could be -70% on a readout. An entire industry of consultants, CROs, and pay-to-play sites/investigators helps pharma companies do this. You can’t fake chemistry and pharmacology, however. We have a particular focus on forensic pharmacology, with respect to biotech shorts, as a result. That’s there the initial clues are usually buried. You can fake it til you make it inside of a clinical trial setting - especially if your trial is in Ukraine, China, etc - but not in the real world. SLNO found this out rapidly after launch. We don’t think the $ABVX drug will ever make it that far, but if it does the outcome will be similar - only on a scale far larger than for a rare disease drug. Thus, we think people waiving ABVX’s ā€œpositiveā€ Phase 3 clinical results as the basis for their rebuttal are missing the forest for the trees.
3
1
33
3,555
Edited my tweet for a few typos and I guess comments prior to the edit are no longer visible when you do that, but great and relevant post from Adam here teapawt.net/a_may_md/status/212431…
2
345
Another banger
$ABVX Scorpion called Abivax a fraud. To believe that requires the reader to completely dismiss the very large clinical dataset and/or believe this is the greatest conspiracy in the history of medicine by an order of magnitude. Show the falsified records. Show the cancer excess at the dose you’re attacking. Explain why blinded readers saw healthier colons on both scopes and biopsies. The evidence Scorpion made public falls well short of its headline, and they themselves tell you that they've already covered their short position by the time you read through the report. scorpioncapital.com/ Start with 50 mg dose. In June, we estimated 0.59 cancers per 100 patient-years at 50 mg, excluding non-melanoma skin cancer. We kept the doses separate because 50 mg was the dose under scrutiny. Abivax’s July deck put the updated number at 0.64 across 944 patient-years at 50 mg, within its historical ulcerative colitis range of 0.30–0.70. Non-melanoma skin cancer also came in at 0.64, below the company’s 0.70–1.40 benchmark. Those are the 50 mg numbers. teapawt.net/deathtouch2k/status/20… Ā· ir.abivax.com/static-files/b… Yes, the narrower Phase 3 maintenance analysis came in higher. Four cases over 438 patient-years gave you 0.91. The added Part 2 data had two cases over 288 patient-years, or 0.69. One patient had a platelet count over 900,000 at baseline and was later diagnosed with a blood-cell cancer. The other was diagnosed with prostate cancer after roughly three months on the drug. Investigators assessed both as unrelated. Then you get to the full 50 mg dataset and the rate is 0.64. If your case depends on the smaller slice, explain why the rest of the exposure should count for less rather than ignoring it because it's inconvenient to your short report credibility. sec.gov/Archives/edgar/data/… Scorpion’s UVA experiment is a lab measurement of light absorption. The public trial protocol already disclosed animal phototoxicity for obefazimod’s main breakdown product and required sun precautions and skin monitoring. The observed 50 mg skin cancer rate across Phase 2 and 3 still came in below the historical benchmark. That comparison leaves room for a rare or delayed risk, but again no evidence. It makes the sweeping cancer claim a lot harder to sell AND physicians are already screening for skin cancer risk due to OTHER STANDARD OF CARE DRUGS THAT CAUSE CANCER IN THESE PATIENTS AND CAN CONFOUND THE SKIN CANCER FINDINGS IN EXPERIMENTAL DRUG TRIALS. scorpionreports.s3.us-east-2… Ā· cdn.clinicaltrials.gov/large… Ā· ir.abivax.com/static-files/b… Now explain the biopsies. Two blinded Phase 3 trials randomized 1,275 patients. At 50 mg, eight-week remission was 21.7% vs 2.5% on placebo in one trial and 19.8% vs 6.3% in the other. The 25 mg dose missed the main endpoint in the second trial. The 50 mg dose hit it in both. sec.gov/Archives/edgar/data/… Then 580 patients who had responded to obefazimod were randomized again. After 44 more weeks, 51% were in remission on either dose versus 10% after switching to placebo. A normal-looking colon on scope? 42% at 25 mg, 48% at 50 mg, 10% on placebo. Improvement confirmed by both scope and biopsy? 50%, 57%, 10%. If widespread gut-cell damage is your explanation for how this drug works, explain why the tissue looked healthier under the microscope. abivax.com/wp-content/upload… And the evidence goes back further. All three doses improved the main disease-activity score in the 254-patient Phase 2b trial. In the open-label follow-up, 114 of 217 were in remission at two years, with missing results counted as failures. In a separate, selected group that stepped down to 25 mg, 88 of 130 were in remission three years later. That’s a substantial record of follow-up on top of the three blinded Phase 3 trials. sciencedirect.com/science/ar… Ā· academic.oup.com/ecco-jcc/ar… Ā· sec.gov/Archives/edgar/data/… ā€œForeign trialsā€ is doing a lot of work here. The Phase 3 trials enrolled across 36 countries. Eastern Europe accounted for 38% of enrollment. In Western Europe, 50 mg remission was 19.0% vs 5.6% on placebo. In a smaller exploratory North American group, it was 8 of 62 vs 0 of 36, with scopes also favoring treatment. The protocol called for independent central readers who were blinded to treatment and visit order. If Scorpion has evidence of misconduct, show the sites, the records and what happens to the results when those sites are removed. sec.gov/Archives/edgar/data/… Ā· academic.oup.com/ecco-jcc/ar… Ā· abivax.com/wp-content/upload… Ā· cdn.clinicaltrials.gov/large… The ā€œ150-foldā€ experiment used zero cells. ZERO CELLS. Why are we relying on experiments that don't even include living cells when we have thousands of patient years worth of safety data? Scorpion measured about one-fifth of the nominal drug concentration in a cell-free reconstruction, then applied that result to cell data from 2015 to get the 150-fold headline. That raises a question about an old assay. The DDT comparison is based on fat solubility. In people given 50 mg, the parent drug’s plasma half-life was about one hour and its main breakdown product’s was about four days. If the claim is dangerous accumulation in human tissue, show the tissue exposure. scorpionreports.s3.us-east-2… Ā· scorpionreports.s3.us-east-2… Ā· journals.asm.org/doi/10.1128… And the supposedly fictitious biology was measured in patients. Both doses raised miR-124 in blood and colon tissue versus placebo in Phase 3, following the same finding in Phase 2. The Phase 3 analysis included 673 paired sigmoid biopsies, alongside paired rectal biopsies and blood samples. Scorpion can question the old binding assay. It still has to deal with the separate structural work and the biological change measured in actual patients. scorpionreports.s3.us-east-2… Ā· academic.oup.com/ecco-jcc/ar… Ā· pmc.ncbi.nlm.nih.gov/article… Ā· abivax.com/wp-content/upload… The cancer cases deserved a serious look in June. We did the math then, and the expanded 50 mg data landed right within our estimates of background cancer rates in ulcerative colitis patients. Scorpion has a set of lab hypotheses and a fraud headline and completely ignores the fact the drug has show ZERO EVIDENCE OF ANYTHING THEY CLAIM IN THOUSANDS OF HUMAN BEINGS AND THEREFORE IS MOST LIKELY COMPLETELY WRONG. Abivax has two positive 50 mg induction trials, a positive randomized maintenance trial at both doses, and biopsies that show the colon getting healthier. If you want to overturn that record, bring CLINICAL EVIDENCE that can explain it.
1
6
1,007
RT. 🫔
Replying to @ScorpionFund
At least your $SLNO report was based on actual in-human data. What you're saying about $ABVX is late to the story wet lab speculation that has already debunked by the existing in human data which very clearly show malignancy rates within or below the expected background rates...Which even your own tables show! BTW, you seem not to know this, but institutional investors ran these lab studies that you just did years ago already, and those same people ended up becoming some of the company's biggest bulls and current investors. I know you think you published something new here - you didn't. The AhR stuff is old old news. Years late to the story, and the in human data have already played out to $ABVX's favor. I could go on and on listing the absurdities in this document...discussing monkey tox concerns at 500mg/kg/day (~1000x the human dose!!!), concerns over "Chinese data" when ABTECT-2 had literally ZERO Chinese trial sites. You point out preclinical phototoxicity signals and speculate that the company didn't know or didn't do anything about it...yet enhanced skin surveillance was BUILT INTO THE STUDIES PROSPECTIVELY by the company! The company itself not only knew about this, but literally specifically designed the studies to test phototox concerns and either confirm it or rule it out....WHICH IT ULTIMATELY DID rule out. Pointing out that the parent molecule is lipophilic and using that to call it an "agrochemical"... Just laughable sensationalism. We have known the structure of this molecule for over a decade. And BTW, plenty of drugs have lipophilic properties. This is a bizarre and irresponsibly over-sensationalized bit...calling it an "agrochemical"... BTW, your own malignancy event table shows a malignancy rate BELOW background rates....??? You point out that there were zero remissions the placebo arm in one of the trials in the US and call that an outlier that will concern regulators....the expected number of patients to respond in that arm per the results of the rest of the study would have been 1.6 responders on the placebo arm! 0 instead of 1...that's an anomolous signal to you? So ultimately your bear argument is this: "This drug has NOT shown increases in cancer in patients. In fact, it has shown rates at or even BELOW the rates of other drugs approved for this disease that have no black box warning for cancer. But hey, who knows, maybe that will change someday down the road!" BTW, you're aware there's an FDA approved AhR drug on the market already right? One with no cancer risk... You're claiming that AhR agonism is the top secret *true* mechanism of $ABVX's obefazimod and that this is bad because you claim AhR agonism is going to cause cancer... Again, not only is the AhR agonism theory that you're treating as a revelation actually a point that $ABVX *bulls* have believed for literally years already (i.e. not news from you), but there is actually a drug ON THE MARKET today that literally has that as its exact mechanism of action...and it has no labeled risk of carcinogenicity and no studies in humans or animals supporting carcinogenic risk....So you go through all this bluster about AhR pretending it is news (it isn't) and then claiming it is going to cause cancer (even though the data we have very clearly show that it HASN'T), meanwhile, there's already been an AhR drug on the market for years that has never shown a single piece of evidence for carcinogenicity... Like I have said in the past - I had previously agreed with some of your work. This piece is irresponsibly poorly done and the use of the word "fraud" is absolutely egregious and slanderous when your thesis ultimately boils down to..."well, they haven't shown cancer signals yet, but maybe they will someday!" Calling this fraud with the evidence you provide sincerely rises to the level of libel, in my opinion.
15
872
Weren't able to cover the way you hoped huh Scorpion / @Kir_Kahlon ...?
Some time back, ADAR1 tweeted they had interesting lab work and were debating whether to release it. Given their status as a top $ABVX holder, people would likely appreciate it being publicly released; assuming it exists, which we have no reason to doubt. Particularly since they keep alluding to how good it is. We publish our work b/c we welcome public debate and scrutiny,
22
1,651
I didn't initially want to waste my time responding to the claims in this slop because it really is just that self-evidently stupid and biologically / medically illiterate. However, I've decided I will touch on a few. First, a drug's safety profile is dictated by what it does in humans. $ABVX HAS 858 patient years of data from the obefazimod Phase II alone and 1,704 (!!!!!!!!) patient years in total. Over 100 patients have been followed up for 5+ years at this point. In humans, across that time scale, the safety has been impressively clean. Why should we give a shit about some random investor with a clear financial conflict of interest running shitty non-human experiments that have not been peer reviewed or otherwise validated by any third party next to literally thousands of patient years of human data?? The FDA won't. Doctors won't. Patients won't. Second, it should actually be bullish that even these idiots couldn't make up a reason to link obefazimod to the one breast case and the one prostate cancer case that appeared in the 50mg Phase III treatment arm to the drug, you know the now widely debunked claim that caused the summer drop. I guess they were able to figure out that prostate and breast cancer starts years and years and years before it becomes clinically detectable a couple of months into a trial. Congrats guys, really great work. Third, the in-human non-melanoma skin cancer "safety" concerns amount to the 50mg arm of the Phase III trial showing 4 non-melanoma skin cancer cases vs 1 in the placebo group. Others have repeatedly showed that this numbers cases fall within the expected background range of NMSC, especially in UC patients who are at an elevated baseline risks. However, and I don't know how many times this needs to be said, even if you wanted to think that obefazimod raises the risk of NMSCs, NMSCs are barely even considered cancer!! Basal Cell Carcinoma almost never metastasizes (seriously, AI this) and NMSCs are actually ~15x more common (millions per year) than prostate and breast cancer (hundreds of thousands), but we never hear about them because they are considered effectively a non-issue. Most importantly, obe's biggest competitor Rinvoq HAS A BLACK BOXED, WARNING WITH FIVE COMPONENTS, MEANING IN-HUMAN TRIALS SHOWED SAFETY ISSUES TO SUCH AN EXTENT THE FDA PUT ITS MOST SERIOUS WARNING ON THE LABEL FOR FIVE SEPARATE CONSIDERATIONS. Those are: A) Mortality (Increased Risk of Death) B) Malignancies (Cancer) C) Major Adverse Cardiovascular events (Stroke, Heart Attack, Cardiovascular Death etc) D) Serious Infections (which can lead to death) E) Thrombosis (DVT, PEs, etc). So, again even if you wanted to believe that you have a slightly higher risk of basal cell carcinoma bc of obefazimod, the safety profile is definitively superior relative to its key competitor Rinvoq (which Abbvie guided to $10.3Bn for FY26, the majority of which is attributable to UC and CD). You're telling me basal cell carcinoma is going to be a gating issue for obefazimod with the FDA, doctors or patients? Come on. Fourth, they say obe is highly lipophilic, and then say pesticides are also highly lipophilic. This is one of the most asinine comments I've ever seen, so bogus to anyone reasonably familiar with biology, that it's hard to see it as having any other purpose than an attempt to freak out retail. Lipophilic just means the propensity for a molecule to dissolve in lipids relative to water. Pesticides are not toxic because of their lipophilicity. They are toxic because of how they interfere with other molecules and molecular processes in the body. Many drugs that are approved and are in active use are more lipophilic than obefazimod. What matters is what the drug does to the body and guess what, WE CAN SEE WHAT IT DOES ACROSS 1,700+ OF IN-HUMAN PATIENT YEARS. Further, obefazimod's main metabolite (a molecule the body produces by processing obefazimod) exists in the body at FAR, FAR higher concentrations than obefazimod itself, and it is this molecule that is considered to be the primary driver of its efficacy. Notably, it is FAR LESS LIPOPHILIC than obefazimod. For reference, 50mg obefazimod's fasted peak concentrations in plasma were found to be 14ng / dL. while n-glucuronide (main metabolite) existed at 2,600ng / dL. That is a ~185x difference... How are these guys going to base one of their primary short argument's on obe's lipophilic profile, and yet fail to address the metabolite that obe is converted to and dwarf's obe in terms of concentration? Stupid, stupid fools. Fifth, these morons claim their shitty experiments showed that toxicity accumulates preferentially in the GI tract??? So, let me get this straight. Obefazimod treats Ulcerative Colitis (an inflammatory disease of the GI tract) and has shown unprecedented efficacy in humans at doing so. Indeed, one of obe's key differentiators is its efficacy when measured by endoscopic remission (taking a scope and looking at the GI tract to see if there are any signs of an inflamed / diseased colon). It also appears to have anti-fibrotic activity in Chron's Disease. And yet, these idiots are suggesting the primary site of obefazimod's toxicity is in the GI tract??? UC patients are much more sensitive to inflammatory insults. If obe is so toxic to the GI tract.... how is it possible that an inflammatory disease improves by more than is seen with any other drug in the maintenance phase?? This simply does not make sense. Finally, for whatever it's worth, I was long $MDGL and got out immediately after reading the lawsuit by Dr. Charlton claiming they were obfuscating data which I thought had merit. I have no problem with getting out of stock if the facts change or shady behavior emerges. However, it seems to me these guys are not individuals who are simply articulating a controversial, but well-thought out and genuinely held, view. The claims here are so demonstrably bogus, and the disclaimer they stuck on their report that they are going to immediately start covering the position once the short report drops, looks like purely predatory market manipulation, taking advantage of current market and trading dynamics that are likely to drive the short report to have maximum negative impact and maximum profit taking for them. So, fuck you.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientificĀ abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
1
3
61
4,550
This might be the most retarded gibberish I have ever read in my life. The actual thesis here is simple: A) Stock w/ heavy retail presence that are likely to get spooked by this B) Market with limited institutional participation beyond specialists whose long model is generally buy and hold C) Specialists likely stretched thin via blown-up shorts, and specialist books in general being down significantly on the heels of $MRNA, $SLS, etc and terrible performance of a lot of quality biotechs as of late. D) Specialists highly concentrated in $ABVX E) Terrible market conditions Drop a short report and of course the stock is going to get blown up. Incredibly transparent. Wild to see.
NEW: We are short $ABVX Abivax SA - a biotech fraud for the ages. Report now live on our site, along with four scientificĀ abstracts based upon our laboratory experiments. An 11-month investigation, our most intensive research to date.
5
3
1
67
6,057
WaveStrum Life Sciences retweeted
Bodes well for many cos thinking about orphan products. N=36 vs external control $CAMP $SPRB $RARE $JSPR $QURE
Today, we have approved the first treatment shown to help people with an infantile onset form of Niemann-Pick disease type C (NPC) live longer. Approved for adults and children weighing ≄7 kg (about 15 pounds) whose neurological symptoms began before age 6, the approval of this new treatment marks an important milestone for the rare disease community. fda.gov/news-events/press-an…
1
3
28
3,779
Update: $SLS opens at $30. There is no specialist money left. Every consensus long is going to zero. We are all Leopold.
So boys, how much degrossing are we in for today? šŸ˜”
3
1
15
2,468
So boys, how much degrossing are we in for today? šŸ˜”
1
1
15
2,791
Again will have more later but able to listen to most of the call on way to hospital, and just great data from $PEPG 10mg / kg looks to be a best-in-disease drug, regardless of what happens at 12.5mg / kg. Functional markers all improving, the CLCN1 data was great data to see As noted previously albuminuria is a known benign feature of ASO class due to reabsorption competition with the megalin receptor, amongst others, in the proximal tubule. If you don’t see an SAE hypomagnesemia or eGFRcys decline it shouldn’t be a concern. Also, evidence dating back to NHP studies suggests if a problem is going to appear it appears early in dosing See below for rough metrics of competition value from this summer (with Avidity now having failed its Phase III, best splicing improvement they ever showed was 17% and best dyne splicing improvement they ever showed was 27%). $PEPG is currently trading well below this. In fact, it’s still trading below its peak after 15 mg / kg SAD!
Replying to @WaveStrumLS
Select Comps: $RNA: $4.2Bn allocable to DM1 $DYN: $2.1Bn allocable to DM1 $RNA will have a control premium baked in that $DYN does not. However, given $PEPG 's single asset nature and institutional backers, I expect a buyout if they show best-in-disease data in the higher MAD cohorts, the way they did in the SAD cohorts. $PEPG's FD market cap is currently ~$136M. Avidity will read out its Phase III trial in 2H 2026. Dyne will read out its registration trials in Q1 2027 with a confirmatory to follow.
6
1
27
3,382
I will have more thoughts on the $PEPG news later, busy day. Really good to get a win on this readout. Best-in class splicing improvement, clean safety. Just to double click on any remaining concerns about albuminuria. Albuminuria without hypomagnesemia or a DLT in eGFRcys decline should not be concern. This is a known benign feature of ASO class which basically arises because the ASO competes with albumin for reabsorption via certain receptors in the proximal tubule, most notably megalin. Just means more albumin is excreted through the urine. If this had occurred in the context of hypomagnesemia or DLT in eGFRcys that would have been a concern,
Sharing some of my diligence regarding $PEPG, which helps explain why I remain quite bullish into the 10mg / kg MAD readout. I may share more if I have time to get the rest into a distributable format and think it adds something. The headline takeaway is twofold. One, I think the outlier in the 5mg / kg MAD has little bearing on its chances of EDODM1 continuing to show best in disease efficacy in the higher MAD cohorts like it showed it in the SAD cohorts. Two, I think the EDO51 safety data and how it has tracked with EDODM1 substantially increases the likelihood there will be no SAEs at the 10mg / kg MAD dose for EDODM1, and EDODM1 will deliver a strong and commercially competitive safety profile. $PEPG is a one drug company, early stage, and the most advanced drug in its class. So, efficacy and safety risks will always exist and can never be fully ruled out. If EDODM1 fails, it's over and the stock will be crushed, albeit perhaps some value can still be extracted from the remaining cash balance given the heavy institutional ownership and sway over management. This remains a very risky investment. However, if it's successful, I would say that it is at least a 10x return from current levels, possibly a good bit more, especially with a buyout premium, and I think the probability of a strong 10mg / kg MAD make the company highly compelling at currently trading levels if position is appropriately sized. Thread below:
1
1
34
3,023